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A B S T R A C T
Thromboembolic complications following heart valve replacements are rare but a severe situation.
Cerebral infarcts, transient neurologic deﬁcits, and cardiac arrest due to stuck prostheses are among
possible critical outcomes. Diagnosis and appropriate treatment should be initiated rapidly.
Echocardiography plays a signiﬁcant role in diagnosis. Fibrinolysis, anticoagulation with heparin, and
surgical intervention are considered among the treatment modalities. Medical treatment is conducted
according to the valvular condition and the clinical status of the patient. In order to prevent probable
complications and enhance the efﬁciency of ﬁbrinolysis, different approaches have been established
regarding the dose and rate of the medication. In the present case, we report a prosthetic heart valve
thrombosis successfully treated with an administration of low-dose, slow-infusion ﬁbrinolytic agent.
<Learning objective: Valvular thrombotic complications after heart valve replacement operations are
associated with high morbidity and mortality. Efﬁcient and urgent treatment is necessary. Considering
the medical treatment, popular conviction about ﬁbrinolytic therapy has depended on the principal of
‘the more, the better’ to date. However, complications of the ﬁbrinolysis may aggravate hemorrhagic
complications with high doses. In this case report, we aimed to state that low-dose slow-infusion
thrombolysis is as efﬁcient as higher doses with fewer complications.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Prosthetic valve thrombosis (PVT) is a rare and severe
complication seen after heart valve replacement and is associated
with high mortality and morbidity. It is seen in 0.3–1.3% of
prosthetic valves in developed countries [1]. Early diagnosis and
appropriate treatment should be promptly established [2]. Surgical
approach, ﬁbrinolysis, and heparin treatment are considered as
treatments of choice according to the clinical status of the patient.
The optimal treatment modality is widely affected by the valvular
condition [1]. The presence of valvular obstruction or the location
of the thrombotic valve (left or right sided) alter the treatment
approach. Because, a left-sided obstructive valve thrombosis
reveals different symptoms than a right-sided non-obstructive
valve thrombosis, the treatment modality should be adjusted in
accordance with the situation.
Fibrinolytic agents are among the treatment options for this
complication [3]. However, studies on large series revealed high* Corresponding author at: Department of Cardiology, Kafkas University Faculty
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[4–6]. The incidence of complications decreases with low dose and
slow infusion of ﬁbrinolytic therapy [7]. Here we report a case of
PVT with mobile and obstructive thrombus diagnosed on a
bioprosthetic mitral valve and the treatment with low-dose slow
infusion of recombinant tissue-type plasminogen activator (rt-PA)
without complications.
Case report
A 66-year-old female patient was admitted to our clinic with
dyspnea and palpitations for one week. There were no signs of
hemorrhage. Her history included bioprosthetic mitral valve
replacement surgery ﬁve years previously due to rheumatic heart
disease. She had not attended scheduled follow-up visits for two
years. She has used acetylsalicylic acid irregularly and gave up
for the past month. Warfarin was not prescribed by the surgeons
probably because the implanted valve was a bioprosthesis.
Physical examination revealed tachycardia and an attenuated
ﬁrst heart sound. Heart rate was 112/min, arterial blood pressure
was 98/60 mmHg, body temperature was 36.2 8C, and the
respiratory rate was 14/min. Pulmonary auscultation was normal.s reserved.
Fig. 1.
On admission. Transthoracic echocardiography images showing the
mobile thrombus. (A) Thrombus in atrium during systole. (B) Thrombus
between prosthetic valvular leaﬂets during diastole. IVS,
interventricular septum; LA, left atrium; LV, left ventricle; RA, right
atrium; RV, right ventricle.
Fig. 2.
On admission. Transesophageal echocardiography image showing the mobile
ﬁbrinolytic treatment was administered.
A. Karakurt, H.S. Bas¸ bug˘ / Journal of Cardiology Cases 12 (2015) 12–15 13Electrocardiography revealed a sinus rhythm with a biphasic P
wave in V1 derivation. Its duration and amplitude were normal.
Pulmonary conus was prominent and pulmonary vascular
congestion was determined in posteroanterior chest X-ray. The
white blood cell count was 7.91 c/mL (normal: 3.5–10.5 c/mL), and
lymphocyte was 1.37 c/mL (normal: 0.99–5.17 c/mL). C-reactive
protein was 2.98 mg/dl (normal: 0–0.5 mg/dl) and the erythro-
cyte sedimentation rate was measured as 27 mg/L. The hemoglo-
bin, hematocrit, and platelet count was 9.9 g/dl, 28%, and
138,000 c/L respectively. International normalized ratio (INR)
was 1.07 IU, prothrombin time was 13.7 s (normal: 10–15 s), and
activated partial thromboplastin time (aPTT) was 13.2 s (normal:
24–37 s). Blood oxygen saturation was 94%. Other biochemical
tests were entirely normal.
Transthoracic echocardiography (TTE) revealed a mobile
thrombus attached to the left atrial face of the bioprosthetic
mitral valve leaﬂet (Fig. 1A). The thrombus was moving from the
left atrium through the bioprosthetic mitral valve leaﬂets during
diastole (Fig. 1B). The longest diameter of the thrombus was
14.76 mm, the shortest diameter was 7.76 mm, and its area was
0.6 cm2. Trans-bioprosthetic valvular diastolic maximum peak
gradient was 12.5 mmHg. The maximum mean gradient was
8.5 mmHg while the thrombus was passing through the leaﬂets.
In parasternal long-axis two-dimensional (2-D) TTE, the right
ventricle diameter was 2.9 cm, and left ventricular diastolic
diameter was 4.5 cm. Diastolic diameter of the interventricular
septum was 0.8 cm, and the left ventricular posterior wall diastolic
diameter was 0.8 cm. In apical four chamber 2-D TTE, the left atrial
diameter was measured as 5.2 cm  4.7 cm  5.5 cm and the right
atrial diameter was measured as 4.2 cm  3.9 cm. Ascendant aorta
and pulmonary artery diameter were calculated as 3.5 cm and
1.9 cm, respectively. Left ventricular ejection fraction was calcu-
lated as 62% with modiﬁed Simpson technique. There were no
valvular, supravalvular, or infravalvular stenosis in the aortic and
pulmonary artery. First-degree tricuspid insufﬁciency with a peak
gradient of 35 mmHg was encountered. Pulmonary arterial
pressure was 45 mmHg. Vital signs were stable.
Transesophageal echocardiography (TEE) was also performed
to determine the strategy of treatment. TEE revealed a mobile
thrombus attached to the atrial side of the bioprosthetic mitral
valve (Fig. 2). There was no thrombus in left atrial appendage.
With the diagnosis of mobile, obstructive bioprosthetic valve
thrombosis, the patient was admitted to the coronary care
unit. Acetylsalicylic acid (300 mg/day) and standard heparin thrombus attached to the atrial side of the bioprosthetic mitral valve, before the
Fig. 4.
Third day. Transesophageal echocardiogram showing complete lysis of
the thrombus following infusion of the third dose of low-dose slow
infusion of recombinant tissue-type plasminogen activator.
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for maintenance) were started.
As the thrombus was mobile and >10 mm, surgery was
considered initially. However, the patient and her relatives refused
the second operation. Thus, administration of low-dose slow-
infusion time thrombolytic therapy was decided, as the thrombo-
embolic complications are considered to be less according to
guidelines [4,8]. The patient was administered an intravenous
infusion of 25 ml rt-PA (low dose) in 100 ml normal saline, in
>10 h (slow infusion time) three times. Echocardiography was
performed after administration of each infusion of ﬁbrinolytic
therapy to observe status and dimensions of the thrombus.
Additionally, mobile echocardiography was also performed
without recording at 4-h intervals to follow the thrombus burden.
After the ﬁrst dose of therapy, control echocardiography revealed
no regression regarding the thrombus size and burden. Therefore, a
second dose of 25 ml rt-PA was administered to the patient.
Following the second dose of ﬁbrinolytic therapy, TTE and TEE
showed partial regression of the thrombus, leaving a residual size
of 4 mm  3 mm (Fig. 3). Thus, administration of the third 25 ml rt-
PA dose was decided. TTE and TEE revealed complete lysis of the
thrombus with no residue following the third dose of thrombolytic
administration (Fig. 4). In total, 75 mg rt-PA was administered.
During the whole thrombolytic therapy, intravenous UFH was
also administered simultaneously with a daily maintenance dose
of 18 U/kg/h. Targeted aPTT level was between 1.5 and 2.5 times
higher than normal. No clinical complication (systemic peripheral
emboli, bleeding) was observed during and after infusion. Oral
warfarin was initiated after the targeted value of aPTT achieved.
INR level was aimed to be 3–3.5 IU. On the fourth day, INR was
3.16 IU. She was discharged on the sixth day of hospitalization
with prescriptions of acetylsalicylic acid 100 mg and warfarin 5 mg
per day, and one-month follow-up visit was recommended.
Discussion
PVT continues to be a serious complication resulting in high
mortality [2,3,9,10]. PVT rate varies depending on several factors.
These include the type, generation, and thrombogenicity of the
valve. Additionally, location of the valve, intensity of anticoagula-
tion, and multiple clinical risk factors (atrial ﬁbrillation, congestive
heart failure, coronary artery disease, hypercoagulopathy, cancer,
dehydration, infection, etc.) also contribute to the PVT rate [11]. ItFig. 3.
Second day. Transesophageal echocardiogram showing the decrease of
thrombus size after the second dose of low-dose slow infusion of
recombinant tissue-type plasminogen activator.has been reported to occur in 0.5–6% of the left-sided prosthetic
valves and up to 20% of tricuspid prostheses [12]. Although
bioprosthetic valves are less thrombogenic than mechanical valves,
Oliver et al. found bioprosthetic thrombosis as 6% [13].
PVT has been divided into two types, obstructive PVT and non-
obstructive PVT, and this determines therapeutic strategy.
Treatment modalities for obstructive PVT are surgery, ﬁbrinolytic
therapy, and optimal antithrombotic treatment. The European
Society of Cardiology and the European Association for Cardio-
Thoracic Surgery guidelines in 2012 recommend surgery for large
(>10 mm) obstructive thrombus and PVT with thrombus located
in left atrial appendage. Fibrinolysis should be the treatment of
choice, if thrombus is less than 10 mm, if there is no left atrial
thrombus on TEE and if the patient has high surgical risk. The rt-PA
dose is 100 mg (10 mg bolus followed by the infusion of the
remaining amount in 90 min) with UFH infusion; streptokinase
dose is 1,500,000 U (in 60 min) without UFH. But these high-dose
ﬁbrinolytic treatments have the risk of bleeding, and systemic and
recurrent embolism [8]. In our case, surgery was suggested to the
patient because the thrombus was large (>10 mm), obstructive,
and mobile. However, she rejected the surgery, so we started
thrombolytic therapy.
Fibrinolysis carries risks of major and minor bleeding, systemic
embolism, and death [4]. Gupta et al. reported a series of 110 patients
with obstructive PVT undergoing thrombolysis. According to this
study, 108 patient received standard streptokinase protocol
(250,000 U in 30 min, followed by 100,000 U/h), and two received
urokinase [5]. Complete hemodynamic improvement was observed
in 81.8% (90/110) of the patients, and partial improvement in
10%. There were 19.1% embolic episodes, 19% bleeding, and 7.3%
deaths during therapy. Roudaut et al. reported their study of
127 instances of non-obstructive PVT treated with ﬁbrinolysis
[1]. Complete resolution of hemodynamic abnormalities was seen in
70.9% and partial resolution in 17.2%. The rates of major bleeding,
systemic embolism, and mortality rate were reported as 4.7%, 15%,
and 11.8%, respectively. There were no signiﬁcant differences in the
rates of complications among different agents employed. These
results are close to those of the study of Gupta et al. [5].
Karthikeyan et al. randomized 120 patients with PVT. The
patients received either a standard infusion of streptokinase
(0.25 MU over 30 min, followed by 0.1 MU/h 72–96 h) or an
accelerated infusion (1.5 MU over 1 h) [6]. Death, major bleeding,
and systemic embolism occurred in 16.7% of the patients. Death
(5% vs. 4%), major bleeding (7% vs. 4%), minor bleeding (8% vs. 5%),
and systemic embolism (4% vs. 2%) did not differ signiﬁcantly
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was associated with high complication rate. There were no
signiﬁcant differences in complications among the different
procedure of the same agents employed.
According to the literature, in the past 10 years only one study
has explored the effect of low-dose slow-infusion ﬁbrinolytic
therapy for the treatment of PVT. In that study, O¨zkan et al.
performed ﬁve different thrombolytic treatment strategies in
patients with PVT [7]. These regimens included rapid streptokinase
(1.5 MU/3 h), slow streptokinase (1.5 MU/24 h), high dose rt-PA
(100 mg, 10 mg bolus, 90 mg/5 h), half-dose slow infusion rt-PA
(50 mg/6 h), and low-dose slow infusion rt-PA (25 mg/6 h).
Treatment success did not differ between the groups. However,
the complication rate was found to be signiﬁcantly lower in the
slow infusion low-dose rt-PA group than in the other groups.
In the present case, the thrombus was mobile and large
(>10 mm), and this led to increased concerns about embolism risk.
Therefore, with the direction obtained from the study performed by
Ozkan et al., the patient was administered intravenous infusion of
25 mg t-PA in 10 h. First ﬁbrinolytic therapy reduced thrombus size
and complete lysis of the thrombus was seen after the second dose of
the ﬁbrinolytic therapy. No additional ﬁbrinolytic therapy was
required. UFH infusion of 70 U/kg was administered before and
during ﬁbrinolytic therapy. This dose and duration of treatment
resulted in complete lysis of the thrombus without thromboembolic
complications. No additional ﬁbrinolytic therapy was required.
In conclusion, traditional ﬁbrinolytic treatment protocols are
associated with high complication rates. Results of the few single
centers, nonrandomized studies consisting of small patient groups
showed that low-dose slow infusion ﬁbrinolytic therapy is
associated with low complication rates. Randomized controlled
studies are needed to determine the complication rates of low-
dose slow infusion of ﬁbrinolytic therapy.
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